Leslie Stolz

Leslie Stolz is a seasoned professional in regulatory affairs and medical communications, currently serving as the Senior Vice President of Regulatory Affairs at Verve Therapeutics since June 2019. Previously, Leslie held positions including Vice President of Regulatory Strategy at Syntimmune (now part of Alexion) from December 2016 to February 2019, and Associate Director of Regulatory Affairs at Shire from February 2016 to November 2016. Additional experience includes Director of Regulatory Affairs at Dyax from January 2014 to January 2016, alongside prior roles at Dyax Corp. and Boston Scientific as a Principal Medical Writer. Leslie’s early career included a Postdoctoral Fellowship at Wyeth Research and a Research Associate position at Thomas Jefferson University. Leslie holds a PhD in Molecular Cancer Biology from Duke University and a BSc in Honors Biology from Villanova University.